Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Large Volume Increase - Should You Buy?

Key Points

• Fresenius Medical Care shares saw elevated trading activity, with roughly 870,298 shares changing hands—15% above average volume—and the stock falling 3.7% to about $21.64.
• Analyst sentiment remains cautious: seven analysts rate the stock “Hold” and four rate it “Sell,” producing an average “Reduce” rating and a consensus price target of $23.42.
• The company exceeded quarterly expectations, reporting $0.66 in earnings per share versus a $0.62 consensus estimate and $5.55 billion in revenue versus $5.48 billion expected. Institutional investors own 8.37% of the shares, with several firms recently increasing their positions.

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) saw unusually-high trading volume on Tuesday. Approximately 870,298 shares changed hands during mid-day trading, an increase of 15% from the average daily volume of 755,991 shares. The stock last traded at $21.6350 and had previously closed at $22.61.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Sanford C. Bernstein lifted their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price target for the company. in a research note on Tuesday, July 28th. Truist Financial decreased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a "hold" rating for the company in a report on Monday, October 12th. Finally, Citigroup reiterated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Seven investment analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Down 3.7%

The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market cap of $11.69 billion, a P/E ratio of 11.27, a P/E/G ratio of 5.28 and a beta of 0.74. The stock has a 50 day moving average price of $22.37 and a 200 day moving average price of $22.87.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.04. The business had revenue of $5.55 billion during the quarter, compared to analysts' expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. Research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Pzena Investment Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 10.8% in the 3rd quarter. Pzena Investment Management LLC now owns 16,617,575 shares of the company's stock worth $371,901,000 after purchasing an additional 1,625,494 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Fresenius Medical Care AG & Co. KGaA by 15.7% during the first quarter. Quantinno Capital Management LP now owns 341,343 shares of the company's stock valued at $7,701,000 after purchasing an additional 46,428 shares during the last quarter. Royal Bank of Canada boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 479.2% during the first quarter. Royal Bank of Canada now owns 216,861 shares of the company's stock worth $4,893,000 after buying an additional 179,418 shares in the last quarter. Assetmark Inc. boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 190.7% during the first quarter. Assetmark Inc. now owns 132,320 shares of the company's stock worth $2,985,000 after buying an additional 86,798 shares in the last quarter. Finally, Sei Investments Co. grew its position in Fresenius Medical Care AG & Co. KGaA by 80.7% in the first quarter. Sei Investments Co. now owns 120,704 shares of the company's stock worth $2,723,000 after buying an additional 53,922 shares during the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.